Diasorin SpA (WBO:DIAS) 1-Year Share Buyback Ratio : -1.00% (As of Dec. 2024 )

View and export this data going back to 2020. Start your Free Trial

What is Diasorin SpA 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Diasorin SpA's current 1-Year Share Buyback Ratio was -1.00%.

WBO:DIAS's 1-Year Share Buyback Ratio is ranked better than
56.79% of 162 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.2 vs WBO:DIAS: -1.00

Competitive Comparison of Diasorin SpA's 1-Year Share Buyback Ratio

For the Diagnostics & Research subindustry, Diasorin SpA's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA's 1-Year Share Buyback Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Diasorin SpA 1-Year Share Buyback Ratio Calculation

Diasorin SpA's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(53.360	-	53.892)	/	53.360
	=	-1.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA (WBO:DIAS) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Diasorin SpA 1-Year Share Buyback Ratio Related Terms

Diasorin SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (WBO:DIAS) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

DSRLF:USA DIA:Italy DIAm:UK 0GZX:UK 34D:Germany

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines